| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(07)61450-0 |
| P698 | PubMed publication ID | 17919718 |
| P2093 | author name string | R H M Verheijen | |
| C J L M Meijer | |||
| P J F Snijders | |||
| F J van Kemenade | |||
| M van Ballegooijen | |||
| K van Groningen | |||
| J Berkhof | |||
| L Rozendaal | |||
| S Bulk | |||
| A J P Boeke | |||
| M E Boon | |||
| F J Voorhorst | |||
| N W J Bulkmans | |||
| W Ruitinga | |||
| P2860 | cites work | Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. | Q51964812 |
| The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. | Q51968734 | ||
| Probabilistic analysis of decision trees using symbolic algebra. | Q52643881 | ||
| Overview of the European and North American studies on HPV testing in primary cervical cancer screening | Q57414808 | ||
| Screening for Genital Human Papillomavirus | Q58296863 | ||
| Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies | Q61881629 | ||
| Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population | Q70655778 | ||
| Observer agreement on interpreting colposcopic images of CIN | Q71919575 | ||
| PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears | Q71937687 | ||
| Cervical cancer screening in the Netherlands | Q73174191 | ||
| High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy | Q73824709 | ||
| Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types | Q73911358 | ||
| Women who participate in spontaneous screening are not at higher risk for cervical cancer than women who attend programme screening | Q77892012 | ||
| Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study | Q78001750 | ||
| Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial | Q79824170 | ||
| Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months | Q79926062 | ||
| Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial | Q83938901 | ||
| Benefit of cervical screening at different ages: evidence from the UK audit of screening histories | Q24651273 | ||
| Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 | ||
| The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays | Q30442823 | ||
| POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women | Q30917882 | ||
| HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial | Q31044179 | ||
| Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral | Q34153160 | ||
| Management of women who test positive for high-risk types of human papillomavirus: the HART study | Q34282635 | ||
| The cervical cancer epidemic that screening has prevented in the UK. | Q34334371 | ||
| Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program | Q35073445 | ||
| Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients | Q35138635 | ||
| The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity | Q35209576 | ||
| PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes | Q35570978 | ||
| The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. | Q35587534 | ||
| American Cancer Society Guidelines for the Early Detection of Cancer, 2005. | Q36015675 | ||
| Clinical relevance of human papillomavirus testing in cytopathology. | Q36109812 | ||
| Human papillomavirus in cervical screening and vaccination | Q36441615 | ||
| A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings | Q36543787 | ||
| Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses | Q36584432 | ||
| Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting | Q36615447 | ||
| Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women | Q36622396 | ||
| Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area | Q36671743 | ||
| Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions | Q37227646 | ||
| Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison | Q37239453 | ||
| The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period | Q40276124 | ||
| The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri | Q40982984 | ||
| Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). | Q43500319 | ||
| Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. | Q50709945 | ||
| Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. | Q50712519 | ||
| Natural history of cervicovaginal papillomavirus infection in young women. | Q50909200 | ||
| P433 | issue | 9601 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervical intraepithelial neoplasia | Q196788 |
| P304 | page(s) | 1764-1772 | |
| P577 | publication date | 2007-10-04 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | |
| P478 | volume | 370 |
| Q37165122 | A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study |
| Q35164373 | A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study |
| Q44511961 | A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. |
| Q37366649 | A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination |
| Q35125113 | A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women |
| Q33545461 | A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial) |
| Q26776336 | A review of the clinical performance of the Aptima HPV assay |
| Q33580897 | A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study |
| Q35018648 | A survey of population-based utility scores for cervical cancer prevention |
| Q26824878 | A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening |
| Q24607403 | American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer |
| Q26828840 | American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. |
| Q55312818 | Analysis of differential gene expression caused by cervical intraepithelial neoplasia based on GEO database. |
| Q34596772 | Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer |
| Q81403462 | Are adjunctive markers useful in routine cervical cancer screening? Application of p16(INK4a) and HPV-PCR on ThinPrep samples with histological follow-up |
| Q37862658 | Assessment of clinical and analytical performance characteristics of an HPV genotyping test |
| Q54781842 | Assessment of new technologies for cervical cancer screening. |
| Q35518164 | Assessment of the performance of algorithms for cervical cancer screening: evidence from the Ludwig-McGill cohort study |
| Q33767458 | Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial |
| Q35124947 | Cervical Cancer Tests and Treatment |
| Q35932079 | Cervical Cytology Specimen Stability in Surepath Preservative and Analytical Sensitivity for HPV Testing with the cobas and Hybrid Capture 2 Tests |
| Q85043418 | Cervical cancer patterns with automation‐assisted and conventional cytological screening: A randomized study |
| Q33875895 | Cervical cancer prevention: new tools and old barriers |
| Q35738881 | Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice |
| Q88381375 | Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up |
| Q37222484 | Cervical cancer screening following prophylactic human papillomavirus vaccination |
| Q94450886 | Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol |
| Q39278591 | Cervical cancer: A global health crisis |
| Q34255316 | Cervical screening: a guideline for clinical practice in Ontario |
| Q34850316 | Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice |
| Q89939929 | Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study |
| Q35036033 | Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control |
| Q37065936 | Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up |
| Q37788742 | Clinical management of HPV‐related disease of the lower genital tract |
| Q34046296 | Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer |
| Q35340725 | Clinical significance of HPV-DNA testing for precancerous cervical lesions |
| Q26771981 | Clinical significance of human papillomavirus genotyping |
| Q37516596 | Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme |
| Q35598854 | Comparative performance of human papillomavirus DNA testing using novel sample collection methods |
| Q36933532 | Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. |
| Q34250191 | Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test |
| Q35066533 | Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening |
| Q36423668 | Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study |
| Q30423690 | Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. |
| Q33704719 | Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening |
| Q44037251 | Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia |
| Q36371450 | Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing |
| Q36057298 | Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening |
| Q38074769 | Current recommendations for cervical cancer screening: do they render the annual pelvic examination obsolete? |
| Q44585146 | Current techniques in screening for cervical cancer in Spain: updated recommendations |
| Q35203251 | Cytology and human papillomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia |
| Q36023019 | Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds |
| Q34627886 | Cytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases |
| Q54411999 | Detection and quantification of human papillomavirus genital infections: virological, epidemiological, and clinical applications |
| Q37452720 | Detection of cervical cancer biomarker patterns in blood plasma and urine by differential scanning calorimetry and mass spectrometry |
| Q82536442 | Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study |
| Q36433491 | Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland |
| Q36826712 | Development and characterization of the cobas human papillomavirus test |
| Q57812823 | Development and interlaboratory agreement of real-time PCR for HPV16 quantification in liquid-based cervical samples |
| Q34486779 | Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape |
| Q38244662 | Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries |
| Q90594835 | Diagnostic Utility of HPV16 E6 mRNA or E7 mRNA Quantitative Expression for Cervical Cells of Patients with Dysplasia and Carcinoma |
| Q36668105 | Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. |
| Q58280692 | EUROGIN 2007 roadmap—Conclusion |
| Q36194955 | EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease |
| Q97435547 | Early posttherapy clearance of human papillomavirus and treatment response in cervical carcinoma |
| Q57896024 | Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months |
| Q30415760 | Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria |
| Q38160099 | Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials |
| Q82586477 | Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial |
| Q57089337 | Embracing a new era in cervical cancer screening |
| Q37941160 | Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies |
| Q54253538 | Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. |
| Q37374869 | Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping |
| Q37289143 | Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening |
| Q36511847 | Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall |
| Q38064070 | Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer |
| Q59558698 | Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis |
| Q58045662 | Feasibility of collecting self-sampled vaginal swabs by mail: quantity and quality of genomic DNA |
| Q37355500 | Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting |
| Q36740029 | Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive |
| Q39276579 | Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis |
| Q92318375 | Genital self-sampling for HPV-based cervical cancer screening: a qualitative study of preferences and barriers in rural Ethiopia |
| Q37697062 | Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma |
| Q37461977 | Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older |
| Q37066141 | Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention |
| Q37595281 | HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway |
| Q35835143 | HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications |
| Q36205998 | HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows |
| Q63976798 | HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology |
| Q22305479 | HPV and Cervical Cancer: Updates on an Established Relationship |
| Q36848123 | HPV immunohistochemical testing and cervical dysplasia |
| Q35595268 | HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs. |
| Q34618650 | HPV testing by cobas HPV test in a population from Catalonia |
| Q81404022 | HPV testing for primary cervical cancer screening |
| Q51824401 | HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. |
| Q34255310 | HPV testing in primary cervical screening: a systematic review and meta-analysis |
| Q33721970 | HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study |
| Q34138292 | HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. |
| Q36071760 | HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice |
| Q90805909 | HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme |
| Q40053521 | HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test |
| Q38069386 | HPV-type has no impact on survival of patients with adenocarcinoma of the uterine cervix |
| Q38385554 | HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in HPV-based cervical cancer precursor screening. |
| Q35868702 | Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany |
| Q37705599 | High-risk HPV nucleic acid detection kit-the careHPV test -a new detection method for screening |
| Q34503722 | High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology |
| Q36118590 | High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology |
| Q41247773 | History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China |
| Q37467429 | How to evaluate emerging technologies in cervical cancer screening? |
| Q84147482 | How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands |
| Q44491735 | HrHPV-testing in a university hospital gynecology outpatient clinic: recommendations for clinical practice |
| Q36675236 | Human Papillomavirus Laboratory Testing: the Changing Paradigm |
| Q35051454 | Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California |
| Q58279986 | Human papillomavirus and cervical cancer |
| Q27023127 | Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts |
| Q37315925 | Human papillomavirus and molecular considerations for cancer risk |
| Q47159754 | Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population |
| Q36845399 | Human papillomavirus genotype specificity of hybrid capture 2 |
| Q43748680 | Human papillomavirus genotyping for the eight oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results |
| Q37271947 | Human papillomavirus infection and the primary and secondary prevention of cervical cancer. |
| Q33978458 | Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia |
| Q45189245 | Human papillomavirus testing for primary cervical cancer screening |
| Q61626075 | Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial |
| Q34616083 | Human papillomavirus testing in the prevention of cervical cancer |
| Q30238772 | Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test. |
| Q35044376 | Immunoprevention of human papillomavirus-associated malignancies |
| Q39665015 | Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening |
| Q59352169 | Implementation of Multicolor Melt Curve Analysis for High-Risk Human Papilloma Virus Detection in Low- and Middle-Income Countries: A Pilot Study for Expanded Cervical Cancer Screening in Honduras |
| Q54468433 | Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme. |
| Q34432811 | Importance of HPV Genotyping for the Screening, Therapy and Management of Cervical Neoplasias |
| Q54242362 | Incidence Trends of Cervical Cancer and Its Precancerous Lesions in Women of Central Switzerland from 2000 until 2014. |
| Q34059732 | Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening |
| Q34490267 | Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach |
| Q40299388 | Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm |
| Q36743797 | Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? |
| Q57791024 | Is routine ECC necessary in patients with HPV16 and normal cytology? |
| Q57089365 | Is the UK ready to embrace HPV testing? |
| Q36688981 | JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix |
| Q40064607 | LINE-1 hypermethylation in white blood cell DNA is associated with high-grade cervical intraepithelial neoplasia. |
| Q36311573 | Laboratory and clinical aspects of human papillomavirus testing |
| Q37621423 | Living with uncertainty: equivocal Pap test results and the evolution of ASC terminology |
| Q37135912 | Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study |
| Q35835177 | Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing. |
| Q92639475 | Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis |
| Q33834332 | Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study |
| Q35669010 | Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting |
| Q33560967 | Major clinical research advances in gynecologic cancer 2009. |
| Q34517694 | Major clinical research advances in gynecologic cancer in 2010 |
| Q26992183 | Major clinical research advances in gynecologic cancer in 2014 |
| Q24198130 | Management of low-grade squamous intra-epithelial lesions of the uterine cervix: repeat cytology versus immediate referral to colposcopy |
| Q36606686 | Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. |
| Q33733302 | Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia |
| Q53278101 | Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex® xMAP™ system. |
| Q34049709 | Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. |
| Q36670003 | Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis |
| Q57226440 | Multinational comparison of diagnostic clues for uterine cervical lesions among cytotechnologists in Asian countries |
| Q37398007 | Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer |
| Q28072213 | New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted Infections |
| Q37306141 | New approaches to cervical cancer screening in Latin America and the Caribbean |
| Q36313296 | New insights into cervical cancer screening. |
| Q33394011 | New paradigms in cervical cancer prevention: opportunities and risks |
| Q34477450 | OGDHL is a modifier of AKT-dependent signaling and NF-κB function |
| Q35788539 | Optical technologies and molecular imaging for cervical neoplasia: a program project update |
| Q40026216 | Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis |
| Q36319941 | Optimizing technology for cervical cancer screening in high-resource settings |
| Q37291430 | Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries |
| Q35605616 | Past and future of prophylactic ablation of the cervical squamocolumnar junction |
| Q37001336 | Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis |
| Q84818275 | Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study |
| Q37302072 | Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia |
| Q84554685 | Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results |
| Q34736619 | Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing |
| Q35223393 | Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer |
| Q91706741 | Population-based primary HPV mRNA cervical screening compared with cytology screening |
| Q37376872 | Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review |
| Q36817519 | Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition |
| Q33708098 | Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. |
| Q40030682 | Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States |
| Q90160108 | Prevalence of HPV-16/18 genotypes and immediate histopathologic correlation results in a Chinese population with negative cytology and positive high-risk HPV testing |
| Q37641787 | Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China |
| Q42408148 | Preventing Cervical Cancer Globally by Acting Locally: If Not Now, When? |
| Q61795801 | Prevention of Cervical Cancer |
| Q33853760 | Previous cervical cytology and high-risk human papillomavirus testing in a cohort of patients with invasive cervical carcinoma in Shandong Province, China. |
| Q37630357 | Primary HPV screening for cervical cancer prevention: results from European trials |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q40961076 | Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory |
| Q34608714 | Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study |
| Q39512938 | Promoter methylation analysis of WNT/β-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. |
| Q39328580 | Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2. |
| Q34062696 | Protecting the underscreened women in developed countries: the value of HPV test |
| Q35324720 | Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme |
| Q41044301 | Recommendation without experts? Epistemological implications in the development of screening guidelines |
| Q37462036 | Risk estimation for the next generation of prevention programmes for cervical cancer |
| Q36365581 | Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study |
| Q51036686 | Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. |
| Q43418991 | Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years |
| Q97586811 | Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening |
| Q35864909 | Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs |
| Q37271280 | Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study |
| Q43585112 | Screening history preceding a diagnosis of cervical cancer in women age 65 and older |
| Q84510280 | Screening: HPV testing for cervical cancer: the good, the bad, and the ugly |
| Q38420219 | Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial |
| Q38828348 | Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial |
| Q35098354 | Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter |
| Q35140046 | Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test |
| Q34113476 | Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models |
| Q37281729 | Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study |
| Q37082560 | Somatic mutation in PIK3CA is a late event in cervical carcinogenesis |
| Q51846056 | State of the science: cervical cancer screening in transition. |
| Q37211860 | Subtype distribution of human papillomavirus in HIV-infected women with cervical intraepithelial neoplasia stages 2 and 3 in Botswana |
| Q35182177 | Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy |
| Q35088687 | Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance |
| Q37218627 | The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening |
| Q57028715 | The Impact of HPV as an Etiological Factor in Gynecological and Oropharyngeal Cancer |
| Q35876962 | The Korean guideline for cervical cancer screening |
| Q26851181 | The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs |
| Q39704260 | The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands |
| Q34330297 | The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologies |
| Q34543764 | The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600) |
| Q35069896 | The indicating FTA elute cartridge a solid sample carrier to detect high-risk HPV and high-grade cervical lesions. |
| Q57792215 | The longitudinal clinical performance of the RNA-based AHPV Human Papillomavirus (HPV) Assay in comparison to the DNA-based Hybrid Capture 2 HPV Test in 2 consecutive screening rounds with a 6-year interval in Germany |
| Q40421489 | The performance of Dynamic Spectral Imaging colposcopy depends on indication for referrals |
| Q39362235 | The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen |
| Q34252947 | The prevalence and role of human papillomavirus genotypes in primary cervical screening in the northeast of China |
| Q42960109 | The role of human papillomavirus testing after treatment for high-grade cervical dysplasia. |
| Q38789321 | Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening |
| Q52566780 | Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening. |
| Q42236931 | Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial |
| Q99590844 | Triage human papillomavirus testing for cytology-based cervical screening in women of different ages in primary hospitals: A retrospective clinical study |
| Q53302283 | Triage of women with atypical squamous cells of undetermined significance (ASC-US): results of an Italian multicentric study. |
| Q51589461 | Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. |
| Q37650670 | Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study |
| Q84613287 | Trials comparing cytology with human papillomavirus screening |
| Q37170521 | Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science |
| Q36799858 | Validation of a DNA methylation HPV triage classifier in a screening sample |
| Q43762516 | Validation of high-risk HPV tests for primary cervical screening |
| Q54306331 | Value of cytologic Papanicolaou smears and polymerase chain reaction screening for human papillomavirus DNA in detecting anal intraepithelial neoplasia: comparison with histology of a surgical sample. |
| Q36094822 | Women's Attitudes Toward Cervicovaginal Self-Sampling for High-Risk HPV Infection on the US-Mexico Border |
| Q35889806 | Women's intentions to receive cervical cancer screening with primary human papillomavirus testing |
| Q38216073 | Worldwide incidence of cervical lesions: a systematic review. |
| Q64256529 | ZNF582 methylation as a potential biomarker to predict cervical intraepithelial neoplasia type III/worse: A meta-analysis of related studies in Chinese population |
| Q36361863 | p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women |
Search more.